Albatsh Musa
Faculty of Pharmacy, Middle East University, Queen Aliaa Airport Street, Amman, 11610, Jordan.
Saudi Pharm J. 2025 Jun 12;33(3):17. doi: 10.1007/s44446-025-00022-6.
Nowadays, the use of unfractionated low molecular weight heparins through intravenous and subcutaneous routes has been limited by several delivery challenges. These include pharmacological activity fluctuations, bleeding issues, and numerous manufacturing restrictions. To address these issues, several efforts have been taken to find alternative routes for this medication. Unfortunately, the past and recent reviews were mainly explored the oral dosage forms of heparin and the other possible indications in practice. This review focuses on emerging efficient and non-invasive heparin options such as buccal, sublingual, oral, rectal and vaginal, transdermal, pulmonary and nasal. To do that, the past and recent studies were categorized into three main groups: (1) Conventional invasive heparin delivery methods; (2) Novel non-invasive heparin delivery systems; and (3) Heparin-based nanoparticles. The main challenges to use non-invasive heparin delivery systems were found to be negative charge and high molecular weight of heparin. Besides, the biological, biophysical, and pharmacological constraints could also limit the benefits of these alternatives. To overcome these issues, the following mechanisms have been used to enhance the delivery of heparin through several routes: (1) Improvement of cell-membrane penetration, (2) Changing of the tight-junctions, (3) Promoting the lipophilicity and (4) Preserving against acidic pH of the stomach. The applicability of alternative delivery options for heparin was mainly affected by overcoming the main penetration barriers. Nanoparticles were found to be effective in increasing the permeability, absorption, bioavailability and bioactivity of heparin.
如今,普通低分子量肝素通过静脉和皮下途径的使用受到了多种给药挑战的限制。这些挑战包括药理活性波动、出血问题以及众多生产限制。为了解决这些问题,人们已做出多项努力来寻找该药物的替代给药途径。遗憾的是,过去和近期的综述主要探讨了肝素的口服剂型以及实际中的其他可能适应症。本综述聚焦于新兴的高效且无创的肝素给药选择,如颊内、舌下、口服、直肠和阴道、经皮、肺部和鼻腔给药。为此,将过去和近期的研究分为三大类:(1) 传统的侵入性肝素给药方法;(2) 新型无创肝素给药系统;(3) 基于肝素的纳米颗粒。使用无创肝素给药系统的主要挑战被发现是肝素的负电荷和高分子量。此外,生物学、生物物理和药理学限制也可能会限制这些替代方法的益处。为克服这些问题,已采用以下机制来增强肝素通过多种途径的给药:(1) 改善细胞膜穿透性;(2) 改变紧密连接;(3) 提高亲脂性;(4) 抵御胃内酸性pH值。肝素替代给药选择的适用性主要受到克服主要渗透屏障的影响。人们发现纳米颗粒在增加肝素的通透性、吸收、生物利用度和生物活性方面是有效的。
Arch Ital Urol Androl. 2025-6-30
Psychopharmacol Bull. 2024-7-8
Cochrane Database Syst Rev. 2018-1-10
Cochrane Database Syst Rev. 2018-1-9
Cochrane Database Syst Rev. 2017-3-3
Cochrane Database Syst Rev. 2024-6-4
Drug Discov Today. 2024-8
Talanta. 2024-6-1
Int J Biol Macromol. 2024-3
Biomed Mater. 2024-1-22
Br J Haematol. 2024-2
Bioact Mater. 2023-8-10
Int J Pharm X. 2023-6-21